Navigation Links
Kidney Transplant Recipients Can Do Away With Steroids

Daily steroids form a major part of anti-rejection medications for kidney transplant recipients. It is well known that long-term steroid use has significant side// effects.

Long-term steroid use is associated with bone disease, obesity and slow growth rate in pediatric patients. Therefore, much effort has been made toward decreasing, withdrawing or completely avoiding the use of steroids in clinical organ transplantation.

A new study in Clinical Transplantation explored a combination of steroid-free medications that resulted in excellent patient outcomes and a very low rejection rate.

A review of 301 patients that were given steroid-free medications at the Ohio State University Medical Center found that only 4.9 percent experienced rejection. In a second review, studying 502 patients who received typical, steroidal medications at the same institution, the rejection rate rose to 9.4 percent.

“The idea behind the research presented is to evaluate the feasibility of omitting the prescription of steroid medications to kidney transplant recipients,” says Amer Rajab, M.D., Ph. D. and lead author of the study. “We conclude that a significantly lower incidence of rejection can be achieved using steroid free maintenance.”

Source-Eurekalert
RI
'"/>




Page: 1

Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. Kidney Stones - Interesting New Research implicates bacteria as its cause
3. Moderate Use of Analgesics - Not Associated With Kidney Dysfunction
4. New Dietary Approach To Manage Kidney Stones
5. Kidney cancer on the rise
6. Kidney function can be affected by lead exposure
7. Kidney Failure after Non-Kidney Transplants
8. Kidney Patients Risk Heart Attacks
9. Kidney Patients Risk Heart Attacks
10. Urine Test for Kidney Cancer
11. New Hope for Kidney Failure
Post Your Comments:
(Date:8/29/2008)...ton Scientific obligation reduced from $250 to $19...tCall/ -- Boston Scientific,Corporation (NYSE: BS...f,Marshall, Texas found two patents of Medtronic, ...onduct during the prosecution of the patents,befor... A jury had previously found that certain Boston S...
(Date:8/29/2008)... Dr. Milton Owens and the Coastal C...rn California to provide protection for cash payin... the Hispanic community is benefiting. , ... 2008 -- Dr. Milton Owens and the Coastal Center f...fornia to provide protection for cash paying patie...
(Date:8/29/2008)... Trusted life science software prov...lients to engage via GSA. , ...ions, an emerging software engineering firm dedic...a U.S. General Services Administration (GSA) Contr...stomers with the ability to conveniently engage 5A...
(Date:8/28/2008)...enues increase 138% versus Q2 2007 - Nine new C.../PRNewswire-FirstCall/ - CRH Medical Corporation,(...he three and six months,ended June 30, 2008 (all f...onths ended June 30, 2008 increased 138% to $1,653...007. Revenue for the six months ended June,30, 200...
Breaking Medicine News(10 mins):Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2Health News:Federal and State Agencies Have Easier Access to 5AM Solutions' Award-Winning Software Services 2Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5
...y published in the May issue of The American Journ...portant role in males as well. Low levels of the f...ure in men, the study found. Those who had low lev...d the greatest risk. The study was conducted by S...
...cancer in women has occurred because of two common...edy from a prevalent chemotherapy medication. Carb...nd lung cancers, is getting known for its success ...tish scientists have conducted a research on mice ...
... anxiety disorder that develops after exposure to ...rding to a study it was found that Vietnam combat ...) //when compared with their non-combat exposed, i... suggests that these deficits are not acquired by ...
...rst partial face transplant patient reports great ...done 5 months back//. Isabelle Dinoire (dee-NWAHR...are more healed and she's recovered total feeling ... two has said she was under the influence of drugs...
Other Medicine News:Health News:Hip Fracture Risk Increases In Men Having Low Estrogen Levels 2Health News:Brain Abnormalities Raise the Risk of PTSD 2
(Date:8/27/2008)...prednisone arm demonstrated a, significant surviv...se -, CAMBRIDGE, Mass., Aug. 27 /- M...nced the publication of results from the 682,patie...eek,s edition of the,New England Journal of Medici...fit and a 30 percent complete remission (CR) rate ...
(Date:8/27/2008)...al, expected by mid-2009 - - Data from second Pha...CKVILLE, Md., Aug. 27 /- Hu...nnounced it has completed enrollment,and initial d... 3,randomized clinical trials of LymphoStat-B(R) (...erythematosus (SLE). Belimumab is being developed ...
(Date:8/26/2008)...mafore Pharmaceuticals Inc.,presented data at the ...es,in Cancer in Washington, D.C., announcing the d... that demonstrate significant anticancer,activity ...molecular scaffold has been developed using,comput...3 kinase inhibitors,as well as isoform-selective s...
(Date:8/26/2008)...FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today a...,from the CUSTOM II trial was published in the mos...ntervention. The lead author of the article was,Dr...nter Utrecht, Utrecht,The Netherlands on behalf o...es across Europe., The one-year CUSTOM II trial, ...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Older Americans are more socially engaged than many people may think 16988 1Older Americans are more socially engaged than many people may think 16988 2Older Americans are more socially engaged than many people may think 16988 3Is there anybody out there 3F 2916 1Is there anybody out there 3F 2916 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 155 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 3MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 1MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 2
...of Peregrine,s,Unique Selective Anti-VEGF Antibodi...l Cancer Models, TUSTIN, Calif., April 20, 2007 /P... Inc. , a clinical stage,biopharmaceutical company... treatment of cancer and hepatitis C virus infecti... presented at the recent,Centennial Annual Meeting...
...Rx Corporation,(NASDAQ:CYTR) today announced that ...clusively licensed to its majority-owned,subsidiar...,published in the April 2007 issue of peer-reviewe...hnology was developed by RXi,Co-founder, Scientifi...setts Medical School (UMMS) Professor of Biochemis...
Other Medicine Technology:Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: